Literature DB >> 28935818

Increased miR-124-3p in microglial exosomes following traumatic brain injury inhibits neuronal inflammation and contributes to neurite outgrowth via their transfer into neurons.

Shan Huang1,2,3, Xintong Ge1,2,4, Jinwen Yu1,2,3, Zhaoli Han2,5, Zhenyu Yin1,2,3, Ying Li2,3, Fanglian Chen2,3, Haichen Wang6, Jianning Zhang2,3,4, Ping Lei7,5.   

Abstract

Neuronal inflammation is the characteristic pathologic change of acute neurologic impairment and chronic traumatic encephalopathy after traumatic brain injury (TBI). Inhibiting the excessive inflammatory response is essential for improving the neurologic outcome. To clarify the regulatory mechanism of microglial exosomes on neuronal inflammation in TBI, we focused on studying the impact of microglial exosomal miRNAs on injured neurons in this research. We used a repetitive (r)TBI mouse model and harvested the injured brain extracts from the acute to the chronic phase of TBI to treat cultured BV2 microglia in vitro The microglial exosomes were collected for miRNA microarray analysis, which showed that the expression level of miR-124-3p increased most apparently in the miRNAs. We found that miR-124-3p promoted the anti-inflamed M2 polarization in microglia, and microglial exosomal miR-124-3p inhibited neuronal inflammation in scratch-injured neurons. Further, the mammalian target of rapamycin (mTOR) signaling was implicated as being involved in the regulation of miR-124-3p by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses. Using the mTOR activator MHY1485 we confirmed that the inhibitory effect of exosomal miR-124-3p on neuronal inflammation was exerted by suppressing the activity of mTOR signaling. PDE4B was predicted to be the target gene of miR-124-3p by pathway analysis. We proved that it was directly targeted by miR-124-3p with a luciferase reporter assay. Using a PDE4B overexpressed lentivirus transfection system, we suggested that miR-124-3p suppressed the activity of mTOR signaling mainly through inhibiting the expression of PDE4B. In addition, exosomal miR-124-3p promoted neurite outgrowth after scratch injury, characterized by an increase on the number of neurite branches and total neurite length, and a decreased expression on RhoA and neurodegenerative proteins [Aβ-peptide and p-Tau]. It also improved the neurologic outcome and inhibited neuroinflammation in mice with rTBI. Taken together, increased miR-124-3p in microglial exosomes after TBI can inhibit neuronal inflammation and contribute to neurite outgrowth via their transfer into neurons. miR-124-3p exerted these effects by targeting PDE4B, thus inhibiting the activity of mTOR signaling. Therefore, miR-124-3p could be a promising therapeutic target for interventions of neuronal inflammation after TBI. miRNAs manipulated microglial exosomes may provide a novel therapy for TBI and other neurologic diseases.-Huang, S., Ge, X., Yu, J., Han, Z., Yin, Z., Li, Y., Chen, F., Wang, H., Zhang, J., Lei, P. Increased miR-124-3p in microglial exosomes following traumatic brain injury inhibits neuronal inflammation and contributes to neurite outgrowth via their transfer into neurons. © FASEB.

Entities:  

Keywords:  PDE4B; extracellular vesicles; glia cells; mTOR signaling; polarization

Mesh:

Substances:

Year:  2017        PMID: 28935818     DOI: 10.1096/fj.201700673R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  119 in total

Review 1.  Circulating Exosomes of Neuronal Origin as Potential Early Biomarkers for Development of Stroke.

Authors:  Ghada Yousif; Shahnaz Qadri; Mahmoud Haik; Yousef Haik; Aijaz Sultan Parray; Ashfaq Shuaib
Journal:  Mol Diagn Ther       Date:  2021-01-16       Impact factor: 4.074

2.  Poster Viewing Sessions PB01-B01 to PB03-V09.

Authors: 
Journal:  J Cereb Blood Flow Metab       Date:  2019-07       Impact factor: 6.200

Review 3.  The role of exosomal microRNAs in central nervous system diseases.

Authors:  Yifei Yu; Kun Hou; Tong Ji; Xishu Wang; Yining Liu; Yangyang Zheng; Jinying Xu; Yi Hou; Guangfan Chi
Journal:  Mol Cell Biochem       Date:  2021-01-29       Impact factor: 3.396

Review 4.  Extracellular miRNAs: From Biomarkers to Mediators of Physiology and Disease.

Authors:  Marcelo A Mori; Raissa G Ludwig; Ruben Garcia-Martin; Bruna B Brandão; C Ronald Kahn
Journal:  Cell Metab       Date:  2019-08-22       Impact factor: 27.287

Review 5.  Epigenetic mechanisms of neurodegenerative diseases and acute brain injury.

Authors:  Mario J Bertogliat; Kahlilia C Morris-Blanco; Raghu Vemuganti
Journal:  Neurochem Int       Date:  2019-12-12       Impact factor: 3.921

Review 6.  Combined bioscaffold with stem cells and exosomes can improve traumatic brain injury.

Authors:  Jiaying Yuan; Benson O A Botchway; Yong Zhang; Xizhi Wang; Xuehong Liu
Journal:  Stem Cell Rev Rep       Date:  2020-04       Impact factor: 5.739

Review 7.  MicroRNA-based therapeutics in central nervous system injuries.

Authors:  Ping Sun; Da Zhi Liu; Glen C Jickling; Frank R Sharp; Ke-Jie Yin
Journal:  J Cereb Blood Flow Metab       Date:  2018-04-30       Impact factor: 6.200

8.  Increases in miR-124-3p in Microglial Exosomes Confer Neuroprotective Effects by Targeting FIP200-Mediated Neuronal Autophagy Following Traumatic Brain Injury.

Authors:  Dai Li; Shan Huang; Zhenyu Yin; Jialin Zhu; Xintong Ge; Zhaoli Han; Jin Tan; Shishuang Zhang; Jing Zhao; Fanglian Chen; Haichen Wang; Ping Lei
Journal:  Neurochem Res       Date:  2019-06-12       Impact factor: 3.996

Review 9.  Exosomal miRNAs in central nervous system diseases: biomarkers, pathological mediators, protective factors and therapeutic agents.

Authors:  Xiaohuan Xia; Yi Wang; Yunlong Huang; Han Zhang; Hongfang Lu; Jialin C Zheng
Journal:  Prog Neurobiol       Date:  2019-09-19       Impact factor: 11.685

10.  [Protective effect of astrocyte exosomes on hypoxic-ischemic neurons].

Authors:  Jing-Lan Huang; Yi Qu; Jun Tang; Rong Zou; Shi-Ping Li; Ya-Fei Li; Li Zhang; Bin Xia; De-Zhi Mu
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2018-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.